Chikungunya Vaccine, Live (cvx 317) Side Effects

Medically reviewed by Drugs.com. Last updated on Dec 29, 2024.

Applies to chikungunya vaccine, live (cvx 317): parenteral injection solution.

Side effects include:

Most common solicited injection site reaction (>10%) was tenderness (10.6%). Most common solicited systemic adverse reactions (>10%) were headache (31.6%), fatigue (28.5%), myalgia (23.9%), arthralgia (17.2%), fever (13.5%), and nausea (11.2%).

For healthcare professionals

Applies to chikungunya vaccine, live (cvx 317): intramuscular powder for injection.

General adverse events

The most commonly reported side effects included headache, fatigue, myalgia, and arthralgia.^[Ref]

Cardiovascular

• Uncommon (0.1% to 1%): Peripheral edema, atrial fibrillation, severe atrial fibrillation
• Frequency not reported: Tachycardia^[Ref]

Dermatologic

• Common (1% to 10%): Rash
• Uncommon (0.1% to 1%): Hyperhidrosis, erythematous rash
• Frequency not reported: Severe rash^[Ref]

Gastrointestinal

• Very common (10% or more): Nausea (up to 11.2%)
• Common (1% to 10%): Vomiting, diarrhea
• Frequency not reported: Severe nausea, severe vomiting^[Ref]

Hematologic

• Very common (10% or more): Grade 1 abnormal neutrophil results (up to 27.6%) grade 1 abnormal leukocyte results (up to 27.3%), grade 1 abnormal lymphocyte results (up to 19.1%), grade 2 abnormal neutrophil results (up to 11.3%)
• Common (1% to 10%): Grade 2 abnormal leukocyte results, grade 3 abnormal neutrophil results, grade 2 abnormal lymphocyte results
• Uncommon (0.1% to 1%): Grade 3 abnormal leukocyte results, grade 4 abnormal neutrophil results, grade 3 abnormal lymphocyte results, lymphadenopathy^[Ref]

Immunologic

• Uncommon (0.1% to 1%): Influenza-like illness
• Frequency not reported: Chikungunya-like adverse reactions^[Ref]

Local

• Very common (10% or more): Injection site tenderness (up to 10.6%)
• Common (1% to 10%): Injection site pain, injection site erythema/redness (at least 2.5 cm), injection site induration (at least 2.5 cm)
• Uncommon (0.1% to 1%): Injection site swelling (at least 2.5 cm)
• Rare (0.01% to 0.1%): Severe injection site pain
• Frequency not reported: Severe injection site tenderness^[Ref]

Metabolic

• Frequency not reported: Hypovolemic hyponatremia, increased brain natriuretic peptide^[Ref]

Musculoskeletal

• Very common (10% or more): Myalgia/muscle pain (up to 23.9%), arthralgia (up to 17.2%)
• Common (1% to 10%): Chills, back pain
• Uncommon (0.1% to 1%): Severe myalgia/muscle pain, severe arthralgia/joint pain, severe back pain
• Frequency not reported: Mild arthralgia, increased troponin, arthritis^[Ref]

Nervous system

• Very common (10% or more): Headache (up to 31.6%)
• Uncommon (0.1% to 1%): Severe headache, dizziness, paresthesia, ataxia, hypoesthesia, peripheral neuropathy, syncope
• Frequency not reported: Prolonged arthralgia, polyarthralgia, nodular swelling of joints in fingers and foot^[Ref]

Other

• Very common (10% or more): Fatigue (up to 28.1%), fever/pyrexia (up to 13.5%)
• Common (1% to 10%): Pain
• Uncommon (0.1% to 1%): Severe fatigue, severe/worse fever, asthenia, feeling abnormal
• Frequency not reported: Prolonged fatigue, severe fever^[Ref]

Respiratory

• Frequency not reported: Tachypnea^[Ref]

See also:

Further information

Chikungunya vaccine, live (cvx 317) side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer